Vincristine (VCR), an analog of Vinblastine (VLB), is a newly isolated alkaloid of the Vinca rosea Linn. VCR has been evaluated in the therapy of a group of 35 patients with Hodgkin's disease and other lymphomas and leukemias previously treated with conventional agents. Clinically significant responses were limited to patients with Hodgkin's disease. Nine of 23 (39 per cent) patients with Hodgkin's disease had temporary remissions lasting 1 month or longer. Toxicity, principally neuromuscular, was frequently encountered and was of such severity was to require discontinuation of therapy in 50 per cent of patients adequately treated. At the present time, VCR is limited to investigational use only.


This work was supported by a grant (CY 3215) from the National Cancer Institute of the United States Public Health Service, and a grant from the Lloyd F. Craver Fund of the Memorial Sloan-Kettering Cancer Center, New York, N.Y.

This content is only available via PDF.